Turkey Tryptophan (11.28.2025)
Dr. Jack Cush reviews the news and reports from this past week on RheumNow.com, including reports on FDA resurrections, FM seasonal worsening, and do you fight switch or swap biologics in PsA TNFi nonresponders?
Vitamin D and Lupus Outcomes (11.21.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
A New Disease Activity Score for Antiphospholipid Syndrome?
EurekAlert!
APS is a systemic autoimmune disorder. It is characterised by the presence of antiphospholipid antibodies and a broad spectrum of clinical features, causing obstetric as well as thrombotic, microvascular and non-thrombotic (TMN) symptoms.
Pulse Steroids and Mycophenolate in Juvenile Dermatomyositis
JAMA Dermatology has published a pilot study demonst
Treating During Pregnancy (11.14.2025)
Dr. Jack Cush reviews the journal articles, news and guidelines from this past week on RheumNow.com
Beyond malignancy, look out for LICATS with CAR-T
CD19 chimeric antigen receptor (CAR) T cell therapy took the centre stage in 2022 where data pertaining to a successful case series of 5 patients with refractory SLE were published by Prof Schett’s group. Since then, this area of therapeutic has expanded exponentially.
ACR 2025 Rheumatology Round Up
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.
ACR25 Best Abstracts - Day 3
Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025.
Are we putting the CAR-T before the horse?
CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure.
Rheumatology’s Blind Spot: The Persistent Exclusion of Older Adults
As the population ages globally, rheumatologists are caring for an increasingly older patient population more than ever before. In rheumatoid arthritis alone, nearly 40 percent of patients are now aged 65 years or older.
New Research Demonstrates Impact of RISE Registry Data on Rheumatology Outcomes
ACR Press Release
New research presented at ACR Convergence 2025 highlights how the Rheumatology Informatics System for Effectiveness (RISE) registry—the nation’s largest colle
GLP-1 Receptor Agonists: Impacts Beyond Metabolism?
The GLP-1 story has been hard to miss this year, and at ACR Convergence, it’s clear that these drugs are starting to make real waves in rheumatology.
Social
Review of neonatal Fc receptor (FcRn) blockers, being developed by J&J, argenx & UCB, showing utility in autoimmune dz as they reduce autoantibodies. FcRn inhibitor market may be worth USD 3.3 billion by 2035. Approved for myasthenia gravis & being developed in Sjögren’s, SLE, https://t.co/mBUla87dK5
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 4 days ago
Beyond malignancy, look out for LICATS with CAR-T
CD19 chimeric antigen receptor (CAR) T cell therapy took the centre stage in 2022 where data pertaining to a successful case series of 5 patients with refractory SLE were published by Prof Schett’s group. Since then, this area https://t.co/JbTB033gti
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
@Janetbirdope’s #ACR25 pearls remind us:
Order ANA only when clinical suspicion exists
Never repeat a positive ANA
ENA only if ANA+
❌ Ignore dsDNA if ANA– (except anti-Ro52)
Stop serial dsDNA/C3/C4 if stable
Smart lab use saves patients anxiety and systems money.
#SLE https://t.co/Mu3EefcIx0
Romatolog @Nurullah_Akkoc ( View Tweet )
1 month ago
Day 4 Recap: ACR Convergence 2025 Highlights https://t.co/CMpbzc4O5x
Great discussion by @EBRheum @AkhilSoodMD @Dr_Brian_MD .
I have always been a FK fan in lupus nephritis as an add on therapy , the only inconvenience is regular monitoring.
@RheumNow
#ACR25
Nouf Al hemmadi @NoufAhmedAlham2 ( View Tweet )
1 month 1 week ago
Prospective RCT on safety & efficacy of TAC+GC vs. MMF+GC
TAC+GC was comparable to MMF+GC as continuous induction maintenance treatment over 96 wks for LN.
AE rates comparable.
TAC - AKI & tremor
MMF - leucopenia
reassuring data.more tx options.
#ACR25 @RheumNow Abs2697 https://t.co/16Fd8zE5dL
sheila @RHEUMarampa ( View Tweet )
1 month 1 week ago
CAR-T Cell Therapies Show Promise for Autoimmune Disease
Two pioneering studies presented at #ACR25 spotlight the potential of CAR-T cell therapies to transform treatment for SLE and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and https://t.co/KdNWmVc4Qc
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Abstract 2694: Neutrophil:Lymphocyte ratio (NLR)- a practical step towards clinical monitoring of interferon?
Log₂NLR significantly correlated with all three IFN signatures across patients with SLE, systemic sclerosis, rheumatoid arthritis, and myositis
@RheumNow #ACR25 https://t.co/ujaOQGvAUV
Akhil Sood MD, MS @AkhilSoodMD ( View Tweet )
1 month 1 week ago
#2659 In a large real-world target trial (>1.3M with T2D), SGLT2 inhibitors, esp dapagliflozin & empagliflozin, were assoc with lower risks of RA, lupus, vasculitis & other autoimmune rheumatic diseases vs DPP-4 inhibitors. Possible immune benefits of SGLT2i? @RheumNow #ACR25
Mrinalini Dey @DrMiniDey ( View Tweet )
1 month 1 week ago
#ACR25 Clinical Preview by Prof Coates to be applied tomorrow!
GC #steroid burden & Mx
Abstr#738 Survey of #GCA patients in US & EU: 3/4 were still on GC; mean 5.3mg/d
Abstr#1526 International consensus of GC taper in #SLE is available & can be applied in clinic
@RheumNow https://t.co/paw7NGjs4p
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 month 1 week ago
Turns out you can directly degrade NETs. Holy smokes
NETs critical in pathology of SLE & other dx
They’ve found you can target it
Enzymatic degrader fused to albumin
Proof-of-concept: degraded a patient’s SLE manifestations in hours
Definitely one to watch
#ACR25 LB22 @RheumNow https://t.co/HVEt8wFYmI
Links:
David Liew @drdavidliew ( View Tweet )
1 month 1 week ago
